MS patients switch drugs to reduce infection risk
NCT ID NCT06854094
Summary
This study compares two approaches for people with relapsing multiple sclerosis who have been on anti-CD20 medications. It examines whether switching to a different drug called cladribine might help reduce infection risks while still controlling MS symptoms. The research follows 70 participants for two years to track infection rates and treatment effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale Regionale di Lugano, Istituto di Neuroscienze Cliniche della Svizzera Italiana, Via Tesserete 46,
Lugano, Canton Ticino, 6903, Switzerland
Conditions
Explore the condition pages connected to this study.